Connection
Antal Zemplenyi to Drug Costs
This is a "connection" page, showing publications Antal Zemplenyi has written about Drug Costs.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.655 |
|
|
|
-
DiStefano MJ, McQueen RB, Zheng H, Gyamfi HG, Ameyaw D, Campbell JD, Zemplenyi A. Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program. Appl Health Econ Health Policy. 2026 03; 24(2):261-269.
Score: 0.836
-
Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 09; 43(9):1147-1160.
Score: 0.819